A 38-year-old woman with acute promyelocytic leukemia (APL) presents to the emergency department with spontaneous bleeding from gums, epistaxis, and petechiae. Laboratory investigations reveal PT 18 s (control 12 s), aPTT 45 s (control 28 s), fibrinogen 85 mg/dL (normal 200–400), D-dimer >5000 ng/mL, and platelet count 35,000/μL. Peripheral blood smear shows abnormal promyelocytes with abundant Auer rods. What is the most appropriate immediate management?

Explanation

## Clinical Context This patient presents with acute promyelocytic leukemia (APL) complicated by disseminated intravascular coagulation (DIC). The laboratory findings are classic: - Prolonged PT and aPTT (consumption of clotting factors) - Severe hypofibrinogenemia (85 mg/dL) - Markedly elevated D-dimer (fibrin degradation) - Thrombocytopenia (35,000/μL) - Clinical bleeding manifestations **Key Point:** APL is the most common cause of DIC in acute leukemias due to release of tissue factor and cancer procoagulant from abnormal promyelocytes. ## Management Strategy **High-Yield:** The immediate approach in APL-associated DIC is: 1. **Supportive transfusion** (FFP, cryoprecipitate, platelets) to replace consumed factors and stabilize hemostasis 2. **Definitive treatment of APL** with ATRA ± arsenic trioxide, which induces differentiation of leukemic promyelocytes and rapidly reverses the DIC 3. **Avoid heparin** in the acute bleeding phase (counterintuitive but critical) **Clinical Pearl:** ATRA causes differentiation of APL blasts within 24–48 hours, leading to: - Resolution of the procoagulant state - Improvement in fibrinogen and platelet counts - Cessation of bleeding This is one of the few scenarios where cytoreduction and differentiation therapy directly resolve DIC. ## Why This Approach Works ```mermaid flowchart TD A[APL + DIC diagnosed]:::outcome --> B[Supportive transfusion]:::action B --> C[Start ATRA/ATO]:::action C --> D[Differentiation of blasts]:::outcome D --> E[Reduced tissue factor release]:::outcome E --> F[DIC resolves]:::outcome F --> G[Hemostasis restored]:::outcome ``` **Key Point:** Heparin is NOT indicated in the acute bleeding phase of DIC; it increases bleeding risk and is reserved only for thrombotic-predominant DIC with ongoing thrombosis despite FFP replacement. ## Supportive Measures | Component | Threshold for Transfusion | |-----------|---------------------------| | Platelets | <20,000/μL or active bleeding | | FFP | PT/aPTT >1.5× control or active bleeding | | Cryoprecipitate | Fibrinogen <100 mg/dL | | RBC | Hgb <7 g/dL or symptomatic | **Warning:** Avoid over-transfusion of RBCs (increases viscosity and thrombotic risk); use restrictive transfusion strategy.